.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF10_Entecavir.Entecavir

Information

Entecavir is a nucleoside analogue with potent and selective activity against hepatitis B virus (HBV). It inhibits the HBV DNA polymerase, reducing viral replication. It is approved for the treatment of chronic hepatitis B infection in adults and pediatric patients over 2 years of age.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects following single oral administration.

References

1. Yoshitsugu, H, et al., & Hiraoka, M (2011). Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. Diagnostic microbiology and infectious disease 70(1) 91–100. DOI:10.1016/j.diagmicrobio.2010.12.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21513847

2. Zhu, M, et al., & Pfister, M (2008). Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. Antimicrobial agents and chemotherapy 52(8) 2836–2841. DOI:10.1128/AAC.01366-07 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18391039

Revisions

• 06/2025 initial generated model